Neurotrope Bioscience, Inc

Diviner Therapeutics is a cutting-edge biotechnology company based in Fairfax, VA, dedicated to developing innovative small molecule technology for the treatment of cancer. Their groundbreaking research focuses on the development of SD133, a first-in-class small molecule inhibitor that targets CDH11, a novel cancer target, and has shown promising results in increasing the survival rate of animals with pancreatic cancer. With funding from prestigious organizations such as the National Institutes of Health (NIH), the Department of Defense (DoD), NIH SBIR awards, and strategic partnerships, Diviner Therapeutics is at the forefront of drug development. Led by a team of experienced scientists, including co-founders Dr. Sivanesan Dakshanamurthy and Dr. Stephen W Byers, the company is actively engaged in advanced preclinical studies to bring tomorrow's therapies to patients today.Generated from the website

Signagen Laboratories is a research facility specializing in genetic engineering and molecular biology services. Their team of experts provides cutting-edge solutions for clients in the biotechnology and pharmaceutical industries. With a focus on innovation and precision, Signagen Laboratories offers customized services to meet the unique needs of each project. Their state-of-the-art facilities and advanced technology ensure high-quality results for all genetic engineering and molecular biology endeavors. Generated from their business information

OriGene Technologies provides innovative technologies for large-scale gene function analyses. OriGene s flagship product is the TrueClone Collection, a searchable source of more than 24,000 human full-length cDNA clones suitable for transfection and protein expression. These cDNAs are suitable for transfection and in vivo or direct in vitro expression. The TrueClone Collection cDNA clones are obtained directly from plasmid cDNA libraries and avoid the sequence errors introduced by other cloning methods. OriGene has commercialized an extensive gene bank of authentic cDNA clones in a standard expression vector. In combination with related gene expression reagents, the company s offerings enable high-throughput functional analysis and the determination of disease specificity. OriGene was founded in 1997 and is based in Rockville, Md.